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Introduction
Tuberculosis in children is a serious and
challenging problem both from diagnostic and
treatment perspectives. This is mainly because of
the paucibacillary nature of the disease and the
absence of a gold standard like isolation of tubercle
bacilli for confirmation in the majority of patients.
The diagnosis is usually presumptive, based on a
positive tuberculin test, contact with a known case
of open pulmonary tuberculosis and an abnormal
chest radiograph suggestive of tuberculosis.
There are a number of reports on the efficacy of
SCC in the treatment of adult pulmonary
tuberculosis but information regarding the value or
the same in the treatment of childhood tuberculosis
is limited. A chemotherapy study was, therefore.
undertaken by the Tuberculosis Research Centre in
collaboration with the Institute of Child Health and
Hospital for Children, Chennai, from where the
patients were drawn. The findings of the same are
presented in this paper.
Plan and conduct of the study
Children aged between 1 and 12 years, who had
not received more than 2 weeks of previous anti-
tuberculosis treatment and had no evidence of renal
or hepatic disease were admitted to the study.
Patients with associated lymphadenitis and minimal
pleural effusion not warranting a pleural tap were
also considered eligible while those with massive
pleural effusion, other forms of extrapulmonary
tuberculosis and isolated bronchiectasis were
excluded.
Criteria for diagnosis
The diagnosis was based mainly on the radiolog-
ical abnormalities which were classified as most
probably TB (Category A) and probably TB (Cate-
gory B). The criteria recommended by the Task
Force set up by the ICMR were adopted with slight
modifications. The radiographs were read by an in-
dependent assessor (Dr. Elizabeth John, Professor
of Radiology, Institute of Child Health, Chennai),
who was not posted with the clinical findings about
the patients. Category A included patients with a
primary focus plus hilar adenitis, mediastinal adeni-
tis, miliary tuberculosis and progressive primary
complex. These patients were started on anti-tuber-
culosis drugs. Patients with a doubtful radiological
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abnormality (category B) were started on antibiotics
alone and a repeat chest radiograph taken at the end
of 2 weeks. If the abnormality persisted, they were
admitted to the study.
Investigations
A 1 TU Mantoux test (PPD batch R T 23 with
tween 80) was done and read at 2, 3 (or occasion-
ally 4) days. A full plate radiograph of the chest was
taken at the time of admission and repeated at 2, 6
and 9 months. In category A patients, in addition,
the X-ray was repeated at the end of 2 weeks of
starting anti-tuberculosis treatment. Estimations of
liver function tests, blood urea, plasma creatinine,
routine haematological investigations including
platelet count were done on admission and repeated
subsequently only if necessary. Gastric lavage for
Mycobacterium tuberculosis culture was done on
admission. Wherever possible, sputum for smear
and culture was done. Urine tests for albumin, bile
pigments. acetyl isoniazid and rifampicin were done
on admission, and thereafter for albumin and
isoniazid at monthly intervals till the treatment was
completed. Lymphnode biopsy for
histopathological examination and culture for M.
tuberculosis was undertaken for patients with
lymphnode enlargement.
Chemotherapeutic regimens
Patients were randomly allocated after
stratification according to the 2 categories (A and
B), to one of the following 2 regimens :
Regimen I : 9HR
Isoniazid and rifampicin daily for 9 months.
Regimen II : 2H3R3Z3/4H2R2
Isoniazid, rifampicin and pyrazinamide thrice a
week for the first 2 months followed by isoniazid
and rifampicin twice a week for the next 4 months.
The dosages were as follows : Rifampicin was
administered in a dose of 12 mg/kg (maximum 300
mg), isoniazid 6 mg/kg (maximum 150 mg) for the
daily phase and 15 mg/kg (maximum 300 mg) for
the thrice weekly and twice weekly phases. The
dose of pyrazinamide was 45 mg/kg (maximum 1
gm).
General management
As far as possible, patients were hospitalised for
Table 1. Pre-treatment Characteristics
Age less than 5 years
Positive tuberculin test
Contact with TB patient
BCG scar present
Gastric lavage positive
Sputum culture positive
Lymphnode culture
alone positive
Lymphnode histopath
alone positive
Total culture positive
Confirmation of TB
56%
72%
78%
57%
38 (28%)
2 patients
4 patients
3 patients
43 (32%)
47 (34%)
a minimum period of 2 weeks and more, if
necessary. Subsequent to discharge, patients
admitted to regimen 1 (9 HR) attended once a week
to collect drugs. They were given the drugs under
supervision on the days they attended. In regimen II
2H3R3Z3/4H2R2 patients attended thrice a week for
the first 2 months followed by twice a week for the
next 4 months for supervised chemotherapy. The
progress was assessed at monthly examinations.
After completion of treatment. patients attended
once a month till 24th month.
Results
A total of 141 patients were admitted to the
study. Of these, 4 were excluded from analysis (1
patient missed 26% of the prescribed treatment, 2
others were discharged against medical advice be-
fore completing treatment and the last patient died
of a non-tuberculous cause). Thus. the analysis of
response to treatment was based on 137 patients.
Table 1 shows the pretreatment characteristics.
On admission, 77 (56%) patients were aged less
than 5 years. Fifty six (41%) patients were classi-
fied as category A and the remaining 81 (59%) as
category B. Of the total patients. 68 (50%) received
regimen I and 69 (50%) regimen II. Tuberculin test
with 1 TU was positive with an induration of 10mm
or more in 98 (72%) patients and BCG scar was
present in 78 (57%). A history of contact with a
known case of pulmonary tuberculosis was present
in 107 (78%). Resting gastric juice was positive for
M. tuberculosis in 38 (28%) patients and sputum
culture alone in 2 patients. Lymphnode biopsy was
undertaken in 12 patients, of whom, in 10 the
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Table 2. Radiological findings on admission Response to treatment
Type of lesion No. of patients %
Parenchymal 68 50
Adenitis
Mediastinal 19
Hilar 13 25
Both 2
Adenitis + Parenchymal 25 18
Cavitary 10 7
All 137 100
Table 3. Response to therapy (regimen wise)
Regimen Normal Residual TB. Total
lesion
No. % 
death patients
No. % No. %
9HR 41 60 26* 38 1 1 68
2H3R3Z3/
4H2R2 33 48 34@ 49 2 3 69
All 74 54 60** 44 3 2 137
* In 5 patients ATT continued for 3 months
@ In 4 patients ATT continued for 3 months
** includes 2 patients with calcification
histopathological examination was confirmatory.
Lymphnode culture was positive for M. tuberculo-
sis in 7 of 12 patients (including 3 patients for
whom gas t r i c  l avage  was  a l so  pos i t ive ) .
Lymphnode histopathology alone was confirmatory
in 3 patients. Thus, culture was positive for M. tu-
berculosis in a total of 44 (32%) patients and the di-
agnosis of tuberculosis was confirmed in 47 (34%).
Of the 44 culture positive patients (22 in regimen I
and 22 in regimen II) the organisms were resistant
to SHR in 1 (2%), to SH in 2 (5%), to HR in 1 (2%),
S alone in 1 (2%) and H alone in 1 (2%) patient.
Table 3 gives the status at the end of therapy,
regimen wise. The results were similar in both the
regimens (P = 0.3). Of the 137 patients, 3 (2%)
died, in 74 (54%) the radiological lesions
disappeared completely and 60 (44%) had residual
lesions (including 2 patients with calcified lesions).
Of the 74 patients, 41 were in regimen I and 33 in
regimen II. Of the 60 with residual lesions, 26 were
regimen I patients while 34 were in regimen II. Of
these, in 9 patients (5 in regimen I and 4 in regimen
II) the treatment was continued for a further period
of 3 months - in 8 because the lesions showed
minimal or no clearance even though clinically they
had no respiratory symptoms and the ninth patient
developed tuberculous meningitis during the first
month of treatment. Three (2%) patients, 1 in
regimen I and 2 in regimen II died.
Type of lesions
Table 2 shows the type of lesions present in the
patients on admission. Majority, namely, 68 (50%)
patients had parenchymal lesions alone, 34 (25%)
had adenitis alone (mediastinal, hilar or both), 10
(7%) had cavitary lesions while the remaining 25
(18%) had combined lesions.
Table 4 shows the response to therapy according
to the type of radiological lesion. Of the 68 patients
with parenchymal lesions, in 34 the lesions cleared
completely while 33 had residual lesions. One
patient died. Of the 25 patients with combined
lesions (adenitis plus parenchymal), in 8 the
radiographs became normal at the end of treatment,
in 2 there was calcification and the remaining 15
had residual lesions (adenitis in 5 and both adenitis
and parenchymal in the remaining 10). Of the 34
patients with adenitis alone, in 28 the nodes
disappeared completely and the remaining 6 had
residual lesions. Lastly, of the 10 patients with
cavitary lesions, 2 patients died, 4 had complete
clearance of the radiological abnormality and in the
remaining 4 there were residual lesions. The
findings in Table 4 give an impression that the rate
of clearance in nodal lesions was more than that in
parenchymal lesions. This is because the residual
lesions in the combined group (Adenitis +
parenchymal) which accounts for 1.5 patients have
not been taken into account. In all the 15 patients,
the nodes persisted at the end of treatment (even
though the size was considerably reduced) and in 5
patients the parenchymal lesions alone cleared
completely. Thus, of the total 100 patients with
parenchymal lesions, the clearance was complete at
the end of treatment in 51 (51%). Similarly, of the
total 59 patients with adenitis, there was complete
resolution in 36 (61%) patients (Table 5).
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Deaths
Three patients died while on treatment. All were
culture positive (gastric lavage in 2 patients and
sputum in the third). Two patients died in the
second month - the first due to sudden development
of pneumothorax and the second deteriorated
despite regular treatment and had extensive
parenchymal lesions. Both had organisms sensitive
to all the drugs. The third patient died during the
fourth month of treatment and had organisms
resistant to SH and R.
Hepatic toxicity
Three patients developed jaundice - the first (in
Regimen II) during the second month and the
second (in Regimen I) in the third month. The last
patient (in Regimen I) developed hepatitis B
infection in the sixth month. In these patients anti-
tuberculosis treatment was modified. H, R and Z in
the first patient and HR in the remaining 2 patients
were withheld and substituted with SE till the liver
function tests became normal. The allocated
chemotherapy was subsequently resumed.
Exclusions
Two patients who had extensive
bronchopneumonic changes were discharged
against medical advice before completing 1 month
of treatment (one in each regimen). In the first
patient gastric lavage was positive with organisms
resistant to H and she continued treatment from a
private practitioner irregularly after discharge. On
Table 4. Response to therapy according to the type of
radiological lesion
Type of No. of X-ray status at TB.
lesions patients end of treatment deaths
Nor- Calc i -  Res i -
ma1 fied dual
Parenchymal 68 34 0 33 1
Adenitis +
p a r e n c h y m a l  2 5 8 2 15* 0
Adenitis 38 28 0 6 0
Cavitary 10 4 0 4 2
All 137 74 2 58 3
* in 5 only adenitis and in 10 both
follow up she was reported to have died in the third
month. The second patient did not receive any
treatment after discharge and died in the second
month. Gastric lavage was positive with sensitive
organisms.
One patient (9HR) missed 26% of the prescribed
treatment and did not report for the 9th monthly
examination. He was doing well  with no
complaints when seen 2 weeks earlier.
Non-TB death
One patient died of a non-tuberculous cause in
the first month of treatment.
Discussion
Short Course Chemotherapy studies for
pulmonary tuberculosis arc limited. Dingley1 in
1980 used four different regimens, namely, 26
weeks of HZE, HPT, HZR and 78 weeks of HT for
treating pulmonary tuberculosis in children. He
concluded that the radiological response was
satisfactory in all the groups but better with
rifampicin containing regimens. Abernathy2 et al
treated 50 children with tuberculosis (47 with
pulmonary TB. 2 with cervical adenitis and 2 with
tuberculous arthritis) with 9 months of rifampicin
and isoniazid (1 HR/8H2R2). They found that most
of the pulmonary infiltrates cleared in 10 months
while hilar adenopathy rarely cleared in less than 2
years. Varudkar3 treated 20 children with one of the
three regimens - 2 RHE/4 HE, 2 HZE/4 HE and 6
HRE3 and found excellent results in 90% of the
patients. Residual lesions were found only in 10%.
Kulkarni et al 4 compared a 6 month regimen (3
S3H3Z3/3H7E7) with regimens of 9, 12 and 18
months in all forms of tuberculosis and found
patient compliance to be excellent with SCC.
Francisco et al 5  treated 117 children with
pulmonary tuberculosis with 6 months of daily INH
Table 5. Response of nodal/parenchymal lesions
Type Total Resolved Calcified Residual
o f patients
Lesion No. % No. % No. %
A d e n i t i s  5 9 * 36 61 2 3 21 36
Paren-
chymal 100* 51 51 0 0 49 49
* Some patients had combined lesions
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and rifampicin. The results indicated that SCC was
efficacious and did not cause any relapse. Thus,
conclusion drawn by the various authors was that
SCC for tuberculosis in children is safe, effective
and inexpensive.
The results with the 2 regimens used in this
study are similar, indicating that intermittent short
course chemotherapy for six months using 3 drugs
initially is as effective as the nine months daily
therapy with 2 drugs. The clearance of radiological
lesions was complete at the end of treatment in 61%
of the patients with adenitis and 51% with
parenchymal changes. In 2 there were calcified
lesions. Only in 9 patients, treatment had to be
continued for a further period of 3 months. The
residual lesions in the other patients continued to
improve even after stopping treatment. Of the total
60 patients with residual lesions at the end of
therapy, on follow up, there was total clearance in
37, calcification in 3 and in only 20 patients,
minimal residual lesions persisted. All the patients
were clinically asymptomatic.
In this study, we observed that the time taken for
both nodal and parenchymal lesions to resolve was
similar while Abernathy et al2 and Seth6 reported
that nodal lesions take upto 1% - 2 years to clear.
To ensure accuracy in diagnosis we undertook
categorisation of the lesions. In all the patients with
radiological lesions classified as ‘most probable’,
anti-tuberculosis treatment was started, chest
radiographs were repeated at the end of 2 weeks : in
none of the patients did the lesion disappear or
decrease in size. To avoid over-diagnosis, patients
with consolidation (which could be either due to
tuberculosis or non-tuberculous infection) were
treated with a course of antibiotics for a period of
10-13 days and a repeat radiograph taken. Only if
the lesions persisted, anti-tuberculosis treatment
was started. An important feature is that all the
radiographs were read by a radiologist, an
independent assessor, who was not aware of any
details pertaining to the patients.
In conclusion, SCC with intermittent 6 month
regimen was found to be as effective as daily 9
month regimen. The adverse reactions were
negligible. The mortality and the drop out rates
were very low. Radiological clearance at the end
of therapy was similar in both nodal and
parenchymal lesions and the improvement
continued even after stopping the treatment.
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